Harnessing the Power of
Naturally Occurring NK Cells
to Fight Cancer
Indapta Therapeutics is a biotechnology company focused on developing
and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient
natural killer (G-NK) cell therapy to treat multiple types of cancer.
Harnessing the Power of Naturally Occurring NK Cells to Fight Cancer
Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple types of cancer.
ABOUT US
Indapta is a biotechnology company harnessing the natural power of the immune system to fight hematologic and solid cancers with its universal natural killer (NK) cell platform derived from healthy donors. The company’s allogeneic platform is based on a subset of NK cells that are deficient in the FceR1g protein, and are called g-NK cells (g minus NK cells). These cells are particularly potent at killing cancer cells when combined with monoclonal antibodies. Indapta is working to bring this off-the-shelf cellular therapy to cancer patients to address the limitations of currently available immunotherapies. Indapta is based in Houston, TX, and Seattle, WA.
G-NK cell therapy is an off-the-shelf solution, eliminating the need for a patient-specific therapy.
G-NK cell therapy is combined with FDA-approved tumor-targeting antibodies.
SCIENCE AND PLATFORM
Cancer is the leading cause of death worldwide. Current therapies are suboptimal, frequently ineffective and often cause significant side effects.
Immunotherapies are a formidable new mechanism to fight cancer. Designed to boost the immune response, immunotherapies such as G-NK therapy were developed to address the limitations of currently available autologous T-cell therapies.
Indapta is developing a universal, allogeneic NK cell therapy designed to substantially improve the cytotoxicity of antibody therapy in cancer. Engineered by nature to fight cancer and infectious diseases, Indapta’s NK cell platform is based on a naturally occurring subset of natural killer cells known as g-NK cells that that have undergone epigenetic changes including the down-modulation of the FceR1γ chain. Compared to conventional NK cells, g-NK cells demonstrate increased cytokine secretion, higher levels of cytolytic enzymes, a more favorable metabolic profile, increased persistence, and markedly higher antibody dependent cell mediated cytotoxicity (ADCC).
Indapta has demonstrate robust anti-cancer effects in preclinical models of cancer using g-NK cells in combination with rituximab in NHL, and in combination with daratumumab in multiple myeloma. These effects are markedly superior to conventional NK cells in combination with monoclonal antibodies.
Indapta has developed a proprietary process to expand g-NK cells that yields a highly potent product without the need for artificial genetic engineering. The company’s first-in-human Phase 1 trial will treat relapsed/refractory non-Hodgkin’s lymphoma and multiple myeloma patients with g-NK cells in combination with rituximab and daratumumab, respectively.
RECENT NEWS
Indapta CEO, Mark Frohlich, to participate in panel, “Beyond CAR-T, What’s Next for Cell Therapy?
Indapta IND cleared by FDA
Indapta Therapeutics Names Moya Daniels, Sneior Vice President of Regulatory and Clinical Operations
Indapta Therapeutics CEO, Mark Frohlich is interviewed by WuXi Apptec on "Delivering on the Promise of New Modalities"
Indapta Therapeutics CEO, Mark Frohlich, interviewed by the San Francisco Business Times
Indapta Therapeutics names Mark W. Frohlich, MD., Chief Executive Officer and raises over $50 million in series A financing and commitments to Advance Development of G-NK Cell Theraphy to Treat Multiple Types of Cancer
Indapta Therapeutics announces New Preclinical Data Demonstrating Proprietary G-NK Cells Enhance Efficacy of Monoclonal Antibodies in Multiple Myeloma
Indapta Therapeutics announces Ley Managment Team Appointments to Advance into Clinial Trials in 2021
Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics announce Investments to Advance Clinical Development of Natral Killer Cell Therapy
Indapta Therapeutics Appoints Dov Goldstein, M.D., Chief Financial and Business Officer
Indapta Therapeutics Provides Corporate Update
Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy
CORPORATE PRESENTATION
Indapta has demonstrated robust anti-cancer effects in preclinical models of cancer using g-NK cells in combination with rituximab in NHL, and in combination with daratumumab in multiple myeloma. These effects are markedly superior to conventional NK cells in combination with monoclonal antibodies.
PUBLICATIONS
Indapta has demonstrated robust anti-cancer effects in preclinical models of cancer using g-NK cells in combination with rituximab in NHL, and in combination with daratumumab in multiple myeloma. These effects are markedly superior to conventional NK cells in combination with monoclonal antibodies.
Careers
Become a part of our dynamic team at Indapta Therapeutics. Explore all of our current job openings and discover more about each role by checking out the list below.